Ultrasensitive Detection of Target micro-RNAs and Nucleic Acids in Small Volume Blood Samples of Advanced Stage Prostate and Kidney Cancer Patients
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Jacksonville, Florida: 15-008587
- Rochester, Minnesota: 15-008587
Sponsor Protocol Number: 15-008587
About this study
The purpose of this study is to evaluate the feasibility of successfully obtaining serial finger-prick blood samples from castrate resistant prostate cancer and metastatic renal cell cancer patients using a specific (HemaSpot-SE ™) collection kit.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
- Diagnosis of castrate resistant prostate cancer based on standard of clinical care definitions either beginning or receiving standard of care treatments for castrate resistant disease including docetaxel chemotherapy; abiraterone acetate; prednisone; enzalutamide; immunotherapy; cabazitaxel or mitoxantrone chemotherapy or radium-223.
- Diagnosis of metastatic kidney cancer based on standard of clinical care definitions either beginning or receiving standard of care treatments for metastatic kidney cancer including VEGF inhibition; biotherapy; immunotherapy or m-TOR inhibitors.
- Willing to learn to perform a finger prick daily for six days and to be able to use a mail-in Federal Express/UPS kit for shipment.
Exclusion Criteria:
- Unwilling to perform a finger prick for blood draw or unable to follow directions
- Bleeding tendencies (known hemophilia; bleeding diathesis, etc)
- On anti-coagulation using Coumadin; heparin, direct thrombin inhibitors (or similar) medications as part of standard clinical care (aspirin, Plavix like medications or other non-steroidal medication use is not an exclusion factor).
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
|
Jacksonville, Fla.
Mayo Clinic principal investigator Manish Kohli, M.D. |
Closed for enrollment |
|
Rochester, Minn.
Mayo Clinic principal investigator Manish Kohli, M.D. |
Closed for enrollment |
|
More information
Publications
Publications are currently not available